Cancer
FDA halts trial after first CAR T-associated patient death
September 6, 2017Research and Development CAR T, CAR-T, Cancer, FDA, cellectis, leukaemia, patient death, pharma, pharmaceutical
French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy …
Takeda partners up to develop “next generation” CAR T solid tumour therapy
September 4, 2017Research and Development, Sales and Marketing CAR T, CAR-T, Cancer, Noile-Immune, Takeda, pharma, pharmaceuticals
Takeda is set to partner with Noile-Immune Biotech in the development of a “next generation” chimeric antigen receptor T-cell (CAR …
Top Ten most popular articles on Pharmafile.com this week
September 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Trump, drugs, health, life sciences, medicine, pharma, pharmaceutical, top ten
This week saw the news of a breakthrough in bispecific antibody production and Merck KGaA finally secured approval for its …
NICE rejects AstraZeneca’s breast cancer drug Faslodex
September 1, 2017Medical Communications, Sales and Marketing AstraZeneca, Cancer, Faslodex, breast cancer, life sciences, pharma, pharmaceutical
NICE has announced its decision to not recommend AstraZeneca’s breast cancer drug Faslodex (fulvestrant) in women who have oestrogen-receptor-positive, locally …
The September 2017 issue of Pharmafocus is now live!
August 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Cancer Research UK, MSD, Pharmafocus, President trump, Takeda, Trump, charlottesville, life sciences, oncology, pharmaceuticals, phatma
The September edition of Pharmafocus is now available – click here to read online.
New research reports first-ever response of central nervous tumour to CAR T therapy
August 29, 2017Manufacturing and Production, Research and Development CAR T, CAR-T, Cancer, life sciences, lymphoma, medicine, pharma, pharmaceuticals
Researchers at a General Hospital in Massachusetts has reported what they claim is the first response of a nervous system …
Pfizer’s leukaemia drug gets opposing regulatory decisions on either side of the Atlantic
August 18, 2017Medical Communications, Sales and Marketing Besponsa, Cancer, FDA, NICE, Pfizer, leukaemia, pharma, pharmaceutical
Pfizer has received a bittersweet bout of news as it emerges that its drug Besponsa (inotuzumab ozogamicin) has received approval …
Independent research may change the immunotherapy game
August 17, 2017Research and Development Cancer, biotech, drugs, immunotherapy, pharma, pharmaceutical
Immunotherapy treatments that focus on the PD-L1 protein have become some of the most exciting to emerge in cancer treatment. …
New personalised molecular blood test could shake up cancer treatment
August 16, 2017Research and Development Cancer, life sciences, medicine, pharma, pharmaceutical, standford university
A team of researchers at Stanford University have engineered a new, highly-sensitive molecular test to detect and monitor cancer which …
NICE knocks back advanced kidney cancer drug duo
August 14, 2017Sales and Marketing Cancer, Kidney cancer, NICE, medicine, pharma, pharmaceutical
NICE has dished out a double judgement turning down two drugs for advanced renal cell carcinoma, a form of kidney …
Takeda strikes partnership to develop single-drug cancer combo immunotherapies
August 14, 2017Medical Communications, Research and Development, Sales and Marketing Cancer, Takeda, immunotherapy, medicine, pharma, pharmaceuticals
Japanese pharma giant Takeda has announced that it is to partner up with US-based Shattuck Labs in a collaboration to …
Over 1,000 currently active cancer trials spell trouble for patient recruitment
August 14, 2017Medical Communications, Research and Development, Sales and Marketing Cancer, drugs, life sciences, medicine, pharma, pharmaceutical
The number of active clinical trials in the cancer space has reached more than 1,000 and rising, outstripping the number …
Ending the era of $100,000 cancer drugs
August 11, 2017Medical Communications, Research and Development Cancer, biotech, drugs, healthcare, immunotherapy, life sciences, medicine, pharma, pharmaceutical
Paul Workman, Chief Executive and President of the Institute of Cancer Research, examines the spiralling cost of cancer treatments and …
Bayer’s liver cancer drug availability spreads to UK with NICE approval
August 10, 2017Sales and Marketing Bayer, Cancer, NICE, Nexavar, life sciences, liver cancer, pharma, pharmaceutical
NICE has announced that it has given final appraisal recommending Bayer’s Nexavar (sorafenib) for the treatment of advanced hepatocellular carcinoma …
Cancer Research UK partners with Biotecnol to deliver experimental solid tumour drug
August 10, 2017Research and Development, Sales and Marketing Biotecnol, Cancer, Cancer Research UK, drugs, immunotherapy, life sciences, medicine, pharma, pharmaceutical
Cancer Research UK (CRUK) has announced a collaboration with Biotecnol, an immuno-oncology firm focused on the development of multifunctional antibodies …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
